Home › NDC Lookup › Ingredients › Silver Sulfadiazine › 59762-0131-06
Silver Sulfadiazine 10 mg/g Cream, 50 g — NDC 59762-0131-06 package photo
Label image from the product's FDA listing (DailyMed) — may show a different pack size or an older label revision.

Silver Sulfadiazine 10 mg/g Cream, 50 g — NDC 59762-0131-6 (Billing 59762-0131-06)

by Mylan Pharmaceuticals Inc. · 50 g in 1 JAR

This is a package of 50 g of Silver Sulfadiazine 10 mg/g Cream from Mylan Pharmaceuticals Inc., marketed since Jan 2018 and currently FDA-listed; retail pharmacies pay about $0.2596 per g (NADAC). It is the main listing for this product, which comes in 6 package sizes.

NDC 59762-0131-06
🏷️ FDA NDC (as labeled) 59762-0131-6 billing pads the package segment with a zero
This package
Contains50 g Cost per g$0.2596 NADAC Per package$12.98 / 50 g Pack sizes6 compare ↓
Also priced by: Medicaid pays $0.2850/unit · Part D plans $0.2091/unit — full pricing hub ↓
Main listing for product 59762-0131 · Also comes in: 20 g 59762-0131-0 25 g 59762-0131-2 50 g 59762-0131-5 85 g 59762-0131-8 400 g 59762-0131-4
Rx only Brand On market Non-controlled ⇄ Compare with another NDC
🗂️ FDA directory synced Oct 1, 2026 · this listing last changed Jul 24, 2026 · sources: openFDA · FDA label (DailyMed) · FDA Orange & Purple Book · First Databank · CMS NADAC, ASP, Medicare & Medicaid · RxNorm
📋 All sources & update times →

This page is curated, coded, and maintained by

Compiled from public FDA, CMS, DailyMed, NADAC, and related drug data sources. Editorial policy

NDC database record

One package, one record: these facts belong to NDC 59762-0131-6 alone.

Record
FDA NDC Directory package listing · Human prescription drug
Code segments
59762 labeler · 0131 product · 6 package
Package marketed since
Jan 16, 2018
Sample package
No — commercial package
Listing certified through
Dec 31, 2026
Billing quantity
50 g per package
Barcode (UPC-A, from the NDC)
3 5976201316 3
Medicaid fills, this package
2,451 prescriptions in the last four reported quarters
FDA record last changed
Jul 24, 2026

Identity & classification

Regulatory identifiers FDA, NLM and CMS codes for this package

FDA NDC (as labeled) 59762-0131-6
Product NDC 59762-0131
11-digit billing NDC 59762013106
NCPDP billing unit GM — per gram (weight)
RxCUI 106351
UNII W46JY43EJR
Application # NDA017381
SPL Set ID 7a6a9590-9983-46ff-ae5c-fe95f4e16cb8
Established class (EPC) Sulfonamide Antibacterial
Chemical class Sulfonamides
DEA schedule Non-controlled
Marketing category NDA AUTHORIZED GENERIC
Marketing status On market
FDA listing status Listed (active directory)
Marketing start 2018-01-15
Route TOPICAL
Dosage form CREAM
Substance SILVER SULFADIAZINE
TE code (Orange Book) AB · RLD · RS

Drug-database identifiers Medi-Span GPI and First Databank GCN / HICL / AHFS classification

GPI-14 90450030003710
GPI class Silver sulfADIAZINE
GCN Seq No 007669
GCN 31630
HICL code 003347
Ingredient (HICL) Silver Sulfadiazine
HIC1 code Q
Therapeutic class — broad (HIC1) Ear/Eye/Nose/Rectum/Topical/Vagina/Other
HIC2 code Q5
Therapeutic class — intermediate (HIC2) Agents Acting Principally On The Skin
HIC3 code Q5S
Therapeutic class — specific (HIC3) Topical Sulfonamides
AHFS code 84:04.16.00
AHFS class Astringents, Anti-Infective
FDB label name SILVER SULFADIAZINE 1% CREAM
FDB brand name Silver Sulfadiazine
Legend status F — Federal legend — prescription drug or device
Quick answers
  • GSN (GCN sequence number): 007669
  • GCN: 31630
  • GPI-14 (Medi-Span): 90450030003710
  • HICL (First Databank): 003347
  • AHFS class code: 84:04.16.00
  • RxCUI (RxNorm): 106351
Why two NDCs? The FDA registers this code as 59762-0131-6 — a 5-4-1 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the package segment → 59762-0131-06. Same drug, same package — only the format differs.
Where does this data come from?
Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.

RxNorm drug class

This medicine belongs to the Sulfonamide Antibacterial class.

Pharmacologic class Sulfonamide Antibacterial
Drug family (ATC) Sulfonamides
Where does this data come from?
Therapeutic classes from RxNorm RxClass (U.S. National Library of Medicine) — Established Pharmacologic Class (FDA), ATC drug family (WHO) and mechanism of action, matched by this product’s RxCUI.

Clinical

Label name SILVER SULFADIAZINE 1% CREAM Ingredient Silver Sulfadiazine
📖 What it is MedlinePlus · NLM

Silver sulfadiazine, a sulfa drug, is used to prevent and treat infections of second- and third-degree burns. It kills a wide variety of bacteria. This medication is sometimes prescribed for other uses; ask your doctor or pharmacist for more information.

Read the full MedlinePlus article ↗
📗 Our plain-language guide HelloPharmacist
  • It is used along with other burn care to help prevent and treat serious infection in second- and third-degree burns. It is a topical antimicrobial that goes on the skin only.
  • The burn is cleaned first, and then the cream is applied under sterile conditions in a thin layer, usually once or twice a day. Keep the burn covered with cream and reapply if it r...
  • Some people notice burning, rash or skin color changes. Your white blood cell count can also dip temporarily, usually in the first few days. Call your doctor if you notice anything...
  • Get help for widespread rash, blistering or peeling skin, or signs of a serious allergic reaction. Also report unusual bruising or bleeding, frequent infections, or signs of liver...
📖 Read our full Silver Sulfadiazine guide →

Supplement & herbal interactions

Some supplements/herbs that may interact with Silver Sulfadiazine — tap one for details:

Dimethylsulfoxide (dmso)Moderate Turpentine OilModerate AlchemillaMinor
🌿 Every supplement checked against Silver Sulfadiazine (3 interactions) — ranked by severity →
Where does this data come from?
Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.

Pricing

A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.

Price systemPer gPer package
Retail pharmacies payNADAC · weekly $0.260 $12.98 / 50 g
Medicaid paysCMS SDUD · 12 mo $0.2850 $14.25 / 50 g
Medicare drug plans payPart D · Q2 2026 $0.2091 $10.46 / 50 g
NADAC price history (per g) — tap or hover for the price & month
Jan 2022 Aug 2022 Jan 2026 Sep 2026 $0.260 $0.129
▲ Up 98% over the last 24 months.
Where does this data come from?
NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.

Packaging — all sizes for this product

Package NDCDescription Per unit Per pack Marketing startMarketing endStatus
59762-0131-00 59762-0131-0 1 TUBE in 1 CARTON / 20 g in 1 TUBE $0.4072 / g $8.14 2018-02-09 — Active
59762-0131-02 59762-0131-2 1 TUBE in 1 CARTON / 25 g in 1 TUBE $0.3177 / g $7.94 2018-02-09 — Active
59762-0131-04 59762-0131-4 400 g in 1 JAR $0.1278 / g $51.12 2018-01-16 — Active
59762-0131-05 59762-0131-5 1 TUBE in 1 CARTON / 50 g in 1 TUBE $0.2596 / g $12.98 2018-01-16 — Active
59762-0131-06 You're viewing this Main listing 50 g in 1 JAR $0.2596 / g $12.98 2018-01-16 — Active
59762-0131-08 59762-0131-8 1 TUBE in 1 CARTON / 85 g in 1 TUBE $0.2609 / g $22.18 2018-01-16 — Active

Per g, this pack runs about 103% above the cheapest pack (400 g, $0.1278 vs $0.2596 NADAC).

In Medicaid, this is the most-dispensed pack of this product — about 30% of fills over the last four reported quarters. See all packs ↓

Pack size FAQ

What quantity is in this package?
This package contains 50 g — 50 g in 1 jar.
How does this package differ from NDC 59762-0131-04?
Both are Silver Sulfadiazine 10 mg/g Cream — the drug itself is identical. This page's package is the 50 g one, while NDC 59762-0131-04 is the 400 g package. Per-g NADAC also differs: $0.2596 here vs $0.1278 for the 400 g pack.
What NDC number is used to bill for this package of Silver Sulfadiazine 10 mg/g Cream?
Use the 11-digit billing form listed in the identifiers section of this page. Pharmacy and medical claims use the 11-digit form; the FDA label may print a shorter form of the same code.

Prices are the latest CMS NADAC pharmacy acquisition cost per NDC; per-pack figures are per-unit × pack quantity, shown only when the pack is denominated in the same measure NADAC prices.

Therapeutic equivalents

ProductLabelerPackNADAC/unitTEStatusPrice vs. this
Silver Sulfadiazine 10 mg/gthis 59762-0131-06 Mylan 50 g $0.260 AB Availability likely —
Silver sulfadiazine 10 mg/g 67877-0124-05 Ascend 50 g $0.260 AB Availability likely —
SSD Cream 10 g/1000g 43598-0210-25 Dr 25 g $0.318 AB Availability likely +22%
Silvadene 10 mg/g 61570-0131-20 Pfizer 1 tube $0.433 AB Availability likely +67%
Silvadene 10 mg/g 50090-0230-00 A-S 1 tube — AB FDA listed —
Silver Sulfadiazine 10 mg/g 50090-0607-00 A-S 50 g — AB FDA listed —
Silver Sulfadiazine 10 mg/g 50090-0717-00 A-S 50 g — AB FDA listed —
Silver Sulfadiazine 10 mg/g 50090-0763-00 A-S 25 g — AB FDA listed —
Silver Sulfadiazine 10 mg/g 50090-2152-00 A-S 400 g — AB FDA listed —
Ssd 10 g/1000g 50090-7447-00 A-S 50 g — AB FDA listed —
SSD Cream 10 g/1000g 60760-0962-50 St. 50 g — AB FDA listed —
Silver Sulfadiazine 10 g/1000g 61919-0237-25 DIRECT 25 g — AB FDA listed —
Silver Sulfadiazine 10 mg/g 63187-0023-25 Proficient 25 g — AB FDA listed —
Silver Sulfadiazine 10 mg/g 63629-8768-01 Bryant 20 g — AB Discontinued —
Silver Sulfadiazine 10 mg/g 63629-8769-01 Bryant 25 g — AB Discontinued —
Silver Sulfadiazine 10 mg/g 63629-8770-01 Bryant 50 g — AB Discontinued —
Silver Sulfadiazine 10 mg/g 63629-8771-01 Bryant 50 g — AB Discontinued —
Silver Sulfadiazine 10 mg/g 63629-8772-01 Bryant 85 g — AB Discontinued —
Silver Sulfadiazine 10 mg/g 63629-8773-01 Bryant 400 g — AB Discontinued —
Silver Sulfadiazine 10 g/1000g 68071-2473-05 NuCare 50 g — AB FDA listed —
SSD Cream 10 g/1000g 68071-3867-05 NuCare 50 g — AB FDA listed —
Thermazene Silver Sulfadiazine 10 mg/g 68788-0600-02 Preferred 25 g — AB FDA listed —
SSD Cream 10 g/1000g 68788-8074-02 Preferred 25 g — AB FDA listed —
Silver Sulfadiazine 10 g/1000g 76420-0208-25 Asclemed 25 g — AB FDA listed —
Silver Sulfadiazine 10 mg/g 80425-0221-01 Advanced 50 g — AB FDA listed —
Silver Sulfadiazine 10 mg/g 87063-0078-05 Asclemed 50 g — AB FDA listed —
About this product: this is an authorized generic — the brand-name product marketed without its brand name. Other versions are listed above, least expensive first.
Where does this data come from?
Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.

Availability & generic status

🏛️
2018
On the market since
Jan 2018
📍
2026
Currently FDA-listed
8 years listed
🔒
·
No generic listed yet
brand only
ℹ️No FDA-approved generic found

We did not find an FDA-approved generic match for this exact strength, form and route.

Where does this data come from?
Patents and exclusivity from the FDA Orange Book (small-molecule drugs), refreshed from public FDA data. Generic launch timing is an estimate, not a guarantee.

Inactive Ingredients / Excipients

Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.

🧪 Avoiding an ingredient? See Silver Sulfadiazine inactive ingredients by manufacturer: every current product's list side by side, so you can ask your pharmacy for the version that does not list it.

A current SPL was checked, but it does not contain a structured or narrative inactive-ingredient list for this product. This does not mean the product has no inactive ingredients.
Where does this data come from?
Source: official FDA Structured Product Labeling (SPL) via DailyMed and the openFDA label index. Structured IACT rows and label-wide narrative are kept separate; availability and product-level specificity depend on the submitted label.

Inactive ingredient FAQ

Are inactive ingredients the same for every manufacturer?
No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.
Why might an inactive ingredient be missing?
Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.
Can inactive ingredients matter?
Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.

Manufacturer & labeler

LabelerMylan Pharmaceuticals Inc.
Application holderKING PHARMACEUTICALS LLC
FDA applicationNDA017381 (NDA AUTHORIZED GENERIC)
Labeler code59762
First marketedJan 2018
Product typeHuman Prescription Drug
Portfolio473 products on file

More NDCs from Mylan Pharmaceuticals Inc. labeler code 59762

The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).
Where does this data come from?
Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.

Full prescribing information FDA SPL

The complete FDA label for this product — the official prescribing information, verbatim, section by section. Jump with a chip, search within the label, or expand everything.
🎯 Indications and Usage ⏱️ Dosage and Administration ⛔ Contraindications ⚠️ Warnings 🤒 Adverse Reactions 🤰 Pregnancy 🧒 Pediatric Use 🧓 Geriatric Use 🧬 Clinical Pharmacology 📦 How Supplied / Storage and Handling 📦 Storage and Handling 📋 Description ⚠️ Precautions 🍼 Nursing Mothers 📄 Carcinogenesis, Mutagenesis, Impairment of Fertility 📚 References 📄 Package Label / Principal Display Panel
🎯 Indications and Usage 31 words ▾

INDICATIONS AND USAGE Silver Sulfadiazine Cream 1% is a topical antimicrobial drug indicated as an adjunct for the prevention and treatment of wound sepsis in patients with second- and third-degree burns.

⏱️ Dosage and Administration 168 words ▾

DOSAGE AND ADMINISTRATION Prompt institution of appropriate regimens for care of the burned patient is of prime importance and includes the control of shock and pain. The burn wounds are then cleansed and debrided, and silver sulfadiazine cream 1% is applied under sterile conditions. The burn areas should be covered with silver sulfadiazine cream 1% at all times.

The cream should be applied once to twice daily to a thickness of approximately 1/16 inch. Whenever necessary, the cream should be reapplied to any areas from which it has been removed by patient activity. Administration may be accomplished in minimal time because dressings are not required.

However, if individual patient requirements make dressings necessary, they may be used. Reapply immediately after hydrotherapy. Treatment with silver sulfadiazine cream 1% should be continued until satisfactory healing has occurred, or until the burn site is ready for grafting.

The drug should not be withdrawn from the therapeutic regimen while there remains the possibility of infection except if a significant adverse reaction occurs.

⛔ Contraindications 64 words ▾

CONTRAINDICATIONS Silver Sulfadiazine Cream 1% is contraindicated in patients who are hypersensitive to silver sulfadiazine or any of the other ingredients in the preparation. Because sulfonamide therapy is known to increase the possibility of kernicterus, silver sulfadiazine cream 1% should not be used on pregnant women approaching or at term, on premature infants, or on newborn infants during the first 2 months of life.

⚠️ Warnings 166 words ▾

WARNINGS Absorption of silver sulfadiazine varies depending upon the percent of body surface area and the extent of the tissue damage. Although few have been reported, it is possible that any adverse reaction associated with sulfonamides may occur. Some of the reactions, which have been associated with sulfonamides, are as follows: blood dyscrasias including agranulocytosis, aplastic anemia, thrombocytopenia, leukopenia, and hemolytic anemia; dermatologic and allergic reactions, including life-threatening cutaneous reactions [Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN) and exfoliative dermatitis]; gastrointestinal reactions; hepatitis and hepatocellular necrosis; CNS reactions; and toxic nephrosis.

There is potential cross-sensitivity between silver sulfadiazine and other sulfonamides. If allergic reactions attributable to treatment with silver sulfadiazine occur, continuation of therapy must be weighed against the potential hazards of the particular allergic reaction. Fungal proliferation in and below the eschar may occur.

However, the incidence of clinically reported fungal superinfection is low. The use of silver sulfadiazine cream 1% in some cases of glucose-6-phosphate dehydrogenase-deficient individuals may be hazardous, as hemolysis may occur.

🤒 Adverse Reactions 150 words ▾

ADVERSE REACTIONS Several cases of transient leukopenia have been reported in patients receiving silver sulfadiazine therapy. 1,2,3 Leukopenia associated with silver sulfadiazine administration is primarily characterized by decreased neutrophil count. Maximal white blood cell depression occurs within 2 to 4 days of initiation of therapy.

Rebound to normal leukocyte levels follows onset within 2 to 3 days. Recovery is not influenced by continuation of silver sulfadiazine therapy. An increased incidence of leukopenia has been reported in patients treated concurrently with cimetidine.

Other infrequently occurring events include skin necrosis, erythema multiforme, skin discoloration, burning sensation, rashes, and interstitial nephritis. Reduction in bacterial growth after application of topical antibacterial agents has been reported to permit spontaneous healing of deep partial-thickness burns by preventing conversion of the partial thickness to full thickness by sepsis. However, reduction in bacterial colonization has caused delayed separation, in some cases necessitating escharotomy in order to prevent contracture.

🤰 Pregnancy 87 words ▾

Pregnancy Teratogenic Effects. A reproductive study has been performed in rabbits at doses up to three to ten times the concentration of silver sulfadiazine in silver sulfadiazine cream 1% and has revealed no evidence of harm to the fetus due to silver sulfadiazine. There are, however, no adequate and well-controlled studies in pregnant women.

Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly justified, especially in pregnant women approaching or at term (see CONTRAINDICATIONS ).

🧒 Pediatric Use 15 words ▾

Pediatric Use Safety and effectiveness in pediatric patients have not been established (see CONTRAINDICATIONS ).

🧓 Geriatric Use 68 words ▾

Geriatric Use Of the total number of subjects in clinical studies of silver sulfadiazine cream 1%, seven percent were 65 years of age and over. No overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out.

🧬 Clinical Pharmacology ~1 min read ▾

CLINICAL PHARMACOLOGY Silver sulfadiazine has broad antimicrobial activity. It is bactericidal for many gram-negative and gram-positive bacteria as well as being effective against yeast. Results from in vitro testing are listed below.

Sufficient data have been obtained to demonstrate that silver sulfadiazine will inhibit bacteria that are resistant to other antimicrobial agents and that the compound is superior to sulfadiazine. Studies utilizing radioactive micronized silver sulfadiazine, electron microscopy, and biochemical techniques have revealed that the mechanism of action of silver sulfadiazine on bacteria differs from silver nitrate and sodium sulfadiazine. Silver sulfadiazine acts only on the cell membrane and cell wall to produce its bactericidal effect.

Results of In Vitro Testing with Silver Sulfadiazine Cream 1% Concentration of Silver Sulfadiazine Number of Sensitive Strains/Total Number of Strains Tested Genus & Species 50 μg/mL 100 μg/mL Pseudomonas aeruginosa 130/130 130/130 Xanthomonas (Pseudomonas) maltophilia 7/7 7/7 Enterobacter species 48/50 50/50 Enterobacter cloacae 24/24 24/24 Klebsiella species 53/54 54/54 Escherichia coli 63/63 63/63 Serratia species 27/28 28/28 Proteus mirabilis 53/53 53/53 Morganella morganii 10/10 10/10 Providencia rettgeri 2/2 2/2 Providencia species 1/1 1/1 Proteus vulgaris 2/2 2/2 Citrobacter species 10/10 10/10 Acinetobacter calcoaceticus 10/11 11/11 Staphylococcus aureus 100/101 100/101 Staphylococcus epidermidis 51/51 51/51 β-Hemolytic Streptococcus 4/4 4/4 Enterococcus species 52/53 53/53 Corynebacterium- diphtheriae 2/2 2/2 Clostridium perfringens 0/2 2/2 Candida albicans 43/50 50/50 Silver sulfadiazine is not a carbonic anhydrase inhibitor and may be useful in situations where such agents are contraindicated.

📦 How Supplied / Storage and Handling 57 words ▾

HOW SUPPLIED Silver Sulfadiazine Cream 1% is available in jars containing 50 g ( NDC 59762-0131-6) and 400 g ( NDC 59762-0131-4), and tubes containing 20 g ( NDC 59762-0131-0), 25 g ( NDC 59762-0131-2), 50 g ( NDC 59762-0131-5) and 85 g ( NDC 59762-0131-8). Store at Controlled Room Temperature 20° to 25°C (68° to 77°F).

📦 Storage and Handling 11 words ▾

Store at Controlled Room Temperature 20° to 25°C (68° to 77°F).

📋 Description 82 words ▾

DESCRIPTION Silver Sulfadiazine Cream 1% is a soft, white, water-miscible cream containing the antimicrobial agent silver sulfadiazine in micronized form, which has the following structural formula: Each gram of silver sulfadiazine cream 1% contains 10 mg of micronized silver sulfadiazine. The cream vehicle consists of white petrolatum, stearyl alcohol, isopropyl myristate, sorbitan monooleate, polyoxyl 40 stearate, propylene glycol, and water, with methylparaben 0.3% as a preservative. Silver Sulfadiazine Cream 1% spreads easily and can be washed off readily with water.

Chemical Structure

⚠️ Precautions ~2 min read ▾

PRECAUTIONS General If hepatic and renal functions become impaired and elimination of drug decreases, accumulation may occur, and discontinuation of silver sulfadiazine cream 1% should be weighed against the therapeutic benefit being achieved. In considering the use of topical proteolytic enzymes in conjunction with silver sulfadiazine cream 1%, the possibility should be noted that silver may inactivate such enzymes. Silver Sulfadiazine Cream 1% is for topical use only.

Avoid contact of silver sulfadiazine cream 1% with the eye. Laboratory Tests In the treatment of burn wounds involving extensive areas of the body, the serum sulfa concentrations may approach adult therapeutic levels (8 mg% to 12 mg%). Therefore, in these patients it would be advisable to monitor serum sulfa concentrations.

Renal function should be carefully monitored and the urine should be checked for sulfa crystals. Absorption of the propylene glycol vehicle has been reported to affect serum osmolality, which may affect the interpretation of laboratory tests. Carcinogenesis, Mutagenesis, Impairment of Fertility Long-term dermal toxicity studies of 24 months' duration in rats and 18 months' in mice with concentrations of silver sulfadiazine three to ten times the concentration in silver sulfadiazine cream 1% revealed no evidence of carcinogenicity.

Pregnancy Teratogenic Effects. A reproductive study has been performed in rabbits at doses up to three to ten times the concentration of silver sulfadiazine in silver sulfadiazine cream 1% and has revealed no evidence of harm to the fetus due to silver sulfadiazine. There are, however, no adequate and well-controlled studies in pregnant women.

Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly justified, especially in pregnant women approaching or at term (see CONTRAINDICATIONS ). Nursing Mothers It is not known whether silver sulfadiazine is excreted in human milk. However, sulfonamides are known to be excreted in human milk, and all sulfonamide derivatives are known to increase the possibility of kernicterus.

Because of the possibility for serious adverse reactions in nursing infants from sulfonamides, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother. Geriatric Use Of the total number of subjects in clinical studies of silver sulfadiazine cream 1%, seven percent were 65 years of age and over. No overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out.

Pediatric Use Safety and effectiveness in pediatric patients have not been established (see CONTRAINDICATIONS ).

🍼 Nursing Mothers 74 words ▾

Nursing Mothers It is not known whether silver sulfadiazine is excreted in human milk. However, sulfonamides are known to be excreted in human milk, and all sulfonamide derivatives are known to increase the possibility of kernicterus. Because of the possibility for serious adverse reactions in nursing infants from sulfonamides, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.

📄 Carcinogenesis, Mutagenesis, Impairment of Fertility 41 words ▾

Carcinogenesis, Mutagenesis, Impairment of Fertility Long-term dermal toxicity studies of 24 months' duration in rats and 18 months' in mice with concentrations of silver sulfadiazine three to ten times the concentration in silver sulfadiazine cream 1% revealed no evidence of carcinogenicity.

📚 References 64 words ▾

REFERENCES 1. Caffee F, Bingham H. Leukopenia and silver sulfadiazine. J Trauma. 1982;22: 586–587. 2. Jarret F, Ellerbe S, Demling R. Acute leukopenia during topical burn therapy with silver sulfadiazine. Amer J Surg. 1978;135:818–819. 3. Kiker RG, Carvajal HF, Micak RP, Larson DL. A controlled study of the effects of silver sulfadiazine on white blood cell counts in burned children. J Trauma. 1977; 17:835–836.

📄 Package Label / Principal Display Panel 133 words ▾

PRINCIPAL DISPLAY PANEL - 20 gram Tube Label NDC 59762-0131-0 GREENSTONE ® BRAND silver sulfadiazine cream 1% 20 grams FOR TOPICAL USE ONLY. Avoid contact with the eye. DOSAGE AND USE See accompanying prescribing information. KEEP OUT OF REACH OF CHILDREN Store at Controlled Room Temperature 20° to 25°C (68° to 77°F). Rx only GREENSTONE LOT / EXP PRINCIPAL DISPLAY PANEL - 20 gram Tube Label

PRINCIPAL DISPLAY PANEL - 20 gram Tube Carton NDC 59762-0131-0 GREENSTONE ® BRAND silver sulfadiazine cream 1% 20 grams Rx only PRINCIPAL DISPLAY PANEL - 20 gram Tube Carton

PRINCIPAL DISPLAY PANEL - 50 gram Jar Label NDC 59762-0131-6 GREENSTONE ® BRAND silver sulfadiazine cream 1% 50 grams Rx only FOR TOPICAL USE ONLY Avoid contact with the eye. PRINCIPAL DISPLAY PANEL - 50 gram Jar Label

Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA. Prefer the government’s original formatting? View this label on DailyMed ↗

Medicaid utilization & spend

📍 This exact package only: Medicaid data is reported per full 11-digit NDC — labeler, product and pack size — so every number here is for this package alone, not the drug overall. Other pack sizes report separately.
💊 Pharmacy benefit only: These are Medicaid outpatient pharmacy claims, billed by NDC. They exclude the medical benefit — clinic- or hospital-administered drugs billed under HCPCS J-codes — so drugs used mostly that way (e.g. Avastin, Lucentis, Keytruda) can look low or missing here. That’s expected, not an error.
📅 Q1 2025 – Q1 2026 · 5 quarters of data
ⓘ The newest quarter is usually incomplete when first published; states restate recent quarters in later CMS releases, so the latest figures typically revise upward. State coverage-policy changes can also shift quarter-to-quarter totals.
Prescriptions last 4 qtrs
2.5K
Units reimbursed last 4 qtrs
134.9K
Gross reimbursed last 4 qtrs
$38.5K
Avg / prescription
$15.69
Avg / unit
$0.2850
Latest quarter Q1 2026
618Rx
Medicaid pays / g
$0.2850
gross reimbursed
vs
NADAC / g
$0.2596
acquisition cost
=
Spread
+$0.0254
+10% vs cost
What Medicaid paid per g (before rebates; includes the pharmacy’s dispensing fee) compared with NADAC — the average price pharmacies pay to buy the drug. A positive spread means Medicaid reimbursed more than the purchase price, before manufacturer rebates.
Fee-for-service vs managed care ⓘ
40% FFS 60% MCO
Fee-for-service · 988 Rx Managed care · 1,463 Rx
State Medicaid map
Alaska: no data reported AK Maine: no data reported ME Washington: 850 units · 10.9 per 100k residents WA Idaho: no data reported ID Montana: no data reported MT North Dakota: no data reported ND Minnesota: no data reported MN Wisconsin: 950 units · 16.1 per 100k residents WI Michigan: 23,335 units · 232 per 100k residents MI New York: 17,460 units · 89.2 per 100k residents NY Vermont: no data reported VT New Hampshire: no data reported NH Oregon: 700 units · 16.5 per 100k residents OR Nevada: no data reported NV Wyoming: no data reported WY South Dakota: no data reported SD Iowa: no data reported IA Illinois: 5,100 units · 40.6 per 100k residents IL Indiana: 1,950 units · 28.4 per 100k residents IN Ohio: 7,850 units · 66.6 per 100k residents OH Pennsylvania: 4,570 units · 35.3 per 100k residents PA New Jersey: 10,330 units · 111 per 100k residents NJ Massachusetts: no data reported MA California: 29,725 units · 76.3 per 100k residents CA Utah: no data reported UT Colorado: no data reported CO Nebraska: no data reported NE Missouri: 1,300 units · 21.0 per 100k residents MO Kentucky: 16,540 units · 365 per 100k residents KY West Virginia: 1,150 units · 65.0 per 100k residents WV Virginia: 600 units · 6.9 per 100k residents VA Maryland: 920 units · 14.9 per 100k residents MD Connecticut: 2,950 units · 81.6 per 100k residents CT Rhode Island: no data reported RI Arizona: no data reported AZ New Mexico: no data reported NM Kansas: no data reported KS Arkansas: no data reported AR Tennessee: 2,450 units · 34.4 per 100k residents TN North Carolina: 1,300 units · 12.0 per 100k residents NC South Carolina: 1,100 units · 20.5 per 100k residents SC Delaware: no data reported DE Oklahoma: no data reported OK Louisiana: no data reported LA Mississippi: no data reported MS Alabama: no data reported AL Georgia: 3,150 units · 28.6 per 100k residents GA D.C.: no data reported DC Hawaii: no data reported HI Texas: no data reported TX Florida: 650 units · 2.9 per 100k residents FL
Units reimbursed · per 100k residents
2.9365
gray = no data reported ⓘ
Colors are per 100,000 residents, so big states don’t automatically dominate. Tap or hover a state for its actual totals.
Tap or hover a state
…for its Medicaid breakdown
🏆 Top states by units · per 100k residents
1 Kentucky 365 /100k
2 Michigan 232 /100k
3 New Jersey 111 /100k
4 New York 89.2 /100k
5 Connecticut 81.6 /100k
6 California 76.3 /100k
7 Ohio 66.6 /100k
8 West Virginia 65.0 /100k
National units — by quarter
💵 About the dollar figures: “reimbursed” is what Medicaid paid pharmacies before confidential manufacturer rebates, so the program’s real net cost is lower than these numbers. Fee-for-service and managed-care claims are combined unless split above. Source: CMS State Drug Utilization Data; per-100k rates use 2023 Census population estimates.

Medicaid utilization by pack size

Medicaid (SDUD) totals over the four most recent reported quarters for every package size of this drug — handy when a specific package (e.g. a starter/titration pack) carries little or no Medicaid volume on its own.
50 g this page59762-0131-06 2,451 Rx · $38,451
1 tube59762-0131-05 1,958 Rx · $30,771
400 g59762-0131-04 1,445 Rx · $56,709
1 tube59762-0131-02 1,160 Rx · $13,321
1 tube59762-0131-00 839 Rx · $9,538
1 tube59762-0131-08 380 Rx · $7,827
Drug total (last 4 qtrs): 8,233 Rx · 867,226 units · $156,618 gross reimbursed
Tap a pack size to open its page. Source: CMS State Drug Utilization Data, last 4 quarters.

Medicare Part D spend CMS · PART D · 2026 (Q1)

Medicare Part D (outpatient prescription) spending for Silver Sulfadiazine — the program that covers self-administered drugs. 2 manufacturers.
⚠️ Drug-level data: CMS publishes Part D spending by drug, not by NDC — these figures combine every manufacturer, strength and package size sold under the name Silver Sulfadiazine. That’s a different level of aggregation than the Medicaid card above, which is specific to this exact 11-digit NDC (pack size included), so the two aren’t directly comparable.
Period
Total Part D spend
$2.77M
Claims incl. refills
136.7K
Beneficiaries
106.4K
Spend / beneficiary
$26.00
Spend / claim
$20.23
Trend by period
💵 About the dollar figures: spending is what Part D plans paid before confidential manufacturer rebates, so the program’s real net cost is lower. A blank patient count means fewer than 11 people — CMS hides counts that small to protect privacy. Source: CMS Medicare Quarterly Part D Spending by Drug (data.cms.gov), updated quarterly.
← 59762-0119-01 · Mylan 59762-0170-01 · Mylan →
For educational and professional reference only — not medical advice. Pricing reflects published NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.